AAOMS Annual Meeting

Conference Coverage

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA
FDA
New Biosimilar Approved by the FDA
04/24/2017
The US Food and Drug Administration recently approved the second biosimilar to Remicade for the treatment of immune-disorders.
04/24/2017
bladder
bladder
FDA Approves New First-Line Bladder Cancer Treatment
04/18/2017
The FDA has approved the first and only cancer immunotherapy for the initial treatment of certain bladder cancers.
04/18/2017
bladder
bladder
FDA Approves New First-Line Bladder Cancer Treatment
04/18/2017
The FDA has approved the first and only cancer immunotherapy for the initial treatment of certain bladder cancers.
04/18/2017
bladder
bladder
FDA Approves New First-Line Bladder Cancer Treatment
04/18/2017
The FDA has approved the first and only cancer immunotherapy for the initial treatment of certain bladder cancers.
04/18/2017
Diabetic Retinopathy
Diabetic Retinopathy
FDA Approves New Treatment for Diabetic Retinopathy
04/17/2017
The FDA has approved the first and only option for the treatment of all forms of diabetic retinopathy.
04/17/2017
Diabetic Retinopathy
Diabetic Retinopathy
FDA Approves New Treatment for Diabetic Retinopathy
04/17/2017
The FDA has approved the first and only option for the treatment of all forms of diabetic retinopathy.
04/17/2017
Diabetic Retinopathy
Diabetic Retinopathy
FDA Approves New Treatment for Diabetic Retinopathy
04/17/2017
The FDA has approved the first and only option for the treatment of all forms of diabetic retinopathy.
04/17/2017
Movement Disorders
Movement Disorders
FDA Approves First Drug to Treat Tardive Dyskinesia
04/12/2017
The US Food and Drug Administration has approved a new capsule for the treatment of the neurological disorder tardive dyskinesia.
04/12/2017
Hepatitis C
Hepatitis C
FDA Approves New Options for Pediatric Patients With Hepatitis C
04/07/2017
The FDA has approved 2 new treatment options for children aged 12 to 17 with hepatitis C infection.
04/07/2017
Hepatitis C
Hepatitis C
FDA Approves New Options for Pediatric Patients With Hepatitis C
04/07/2017
The FDA has approved 2 new treatment options for children aged 12 to 17 with hepatitis C infection.
04/07/2017